In another study on breast cancer, novel validated targets of miR-200c, SH3 and PX domains 2A (TKS5), and myosin light chain kinase (MYLK) were downregulated by miR-200c through the ZEB1 pathway (Sundararajan et al., 2015). The gene discussed is MYLK; the disease is breast cancer.